Keyphrases
Bladder Cancer
100%
Hematuria
100%
Epigenetic Profile
100%
Cancer Inpatients
100%
Twist1
75%
ONECUT2
75%
OTX1
75%
Mutation Status
50%
Fibroblast Growth Factor Receptor 3 (FGFR3)
50%
Human Telomerase Reverse Transcriptase (hTERT)
50%
Invasive Examination
50%
Negative Predictive Value
25%
Logistic Regression Analysis
25%
Urine Samples
25%
Patients at Risk
25%
High Sensitivity
25%
Current Clinical Practice
25%
Low Risk
25%
Patient Health
25%
Internal Validation
25%
Health Care Costs
25%
Methylation-specific Polymerase Chain Reaction
25%
Methylation Markers
25%
Methylation Analysis
25%
Risk Prediction
25%
Gross Hematuria
25%
Non-invasive Screening
25%
High Specificity
25%
Epigenetic Profiling
25%
Treatment Burden
25%
Cancer Prevalence
25%
Screening Method
25%
Accurate Model
25%
Cystoscopy
25%
Undetected Cancer
25%
PIK3CA
25%
Microscopic Hematuria
25%
INIS
detection
100%
patients
100%
cancer
100%
evaluation
100%
bladder
100%
sensitivity
42%
risks
42%
methylation
42%
specificity
28%
receptors
28%
mutations
28%
urine
28%
auc
28%
growth factors
28%
fibroblasts
28%
screening
14%
validation
14%
values
14%
cost
14%
regression analysis
14%
dna
14%
polymerase chain reaction
14%
panels
14%
prediction
14%
Medicine and Dentistry
Bladder Cancer
100%
Hematuria
100%
Methylation
75%
Telomerase Reverse Transcriptase
50%
Fibroblast Growth Factor Receptor 3
50%
Logistic Regression Analysis
25%
Prevalence
25%
Sensitivity and Specificity
25%
Health Care Cost
25%
Malignant Neoplasm
25%
Screening
25%
Urine Sampling
25%
Cystoscopy
25%
Polymerase Chain Reaction
25%
Biochemistry, Genetics and Molecular Biology
Methylation
100%
Epigenetics
100%
Telomerase Reverse Transcriptase
66%
HRAS
66%
Fibroblast Growth Factor Receptor 3
66%
Prevalence
33%
Urine Sampling
33%
KRAS
33%
Screening
33%
Polymerase Chain Reaction
33%
Pharmacology, Toxicology and Pharmaceutical Science
Bladder Cancer
100%
Hematuria
100%
Telomerase Reverse Transcriptase
50%
Fibroblast Growth Factor Receptor 3
50%
Prevalence
25%
Malignant Neoplasm
25%